Geron Corp (NAS:GERN)
$ 3.3 0 (0%) Market Cap: 1.99 Bil Enterprise Value: 1.74 Bil PE Ratio: 0 PB Ratio: 6.73 GF Score: 37/100

Geron Corp at B Riley Securities Oncology Conference (Virtual) Transcript

Jan 18, 2023 / 06:00PM GMT
Release Date Price: $3.12 (-1.58%)
Kalpit R. Patel
B. Riley Securities, Inc., Research Division - Healthcare Research Analyst

All right. Good morning, everyone. Thank you for tuning in B. Riley's Oncology Conference. I'm Kalpit Patel, a research analyst here on the biotech team at B. Riley. Our next fireside chat is with a company called Geron, and we have the company's CEO, John Scarlett. Chip, thanks very much for joining us today.

Questions & Answers

Kalpit R. Patel
B. Riley Securities, Inc., Research Division - Healthcare Research Analyst

Maybe we can get started with you had a major clearing event with imetelstat recently in lower-risk MDS. And maybe we can just start with your overall take on hitting the primary endpoint in IMerge. Were there any surprises relative to what you've seen in the Phase II, maybe both on the positive and on the negative sides of the equation?

John A. Scarlett
Geron Corporation - Chairman of the Board, President & CEO

Yes, sure. Thanks, Kalpit. I'll answer that question in a second. First of all,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot